ALPN Live signals | Maximize Profits with Getagraph.com

BUY 4319 min ago

@ $64.97

Issued: 17 May 2024 @ 16:00

Return: 0.00%

Previous signal: May 13 - 12:25

Previous signal: Sell

Return: 0.02 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	4.29M
Average Volume	2.37M
Market Cap	4.46B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.420 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-101.52
ATR14	$0.0290 (0.04%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-08	Peng Stanford L	Buy	13 377	Common Stock
2024-05-08	Peng Stanford L	Buy	26 912	Common Stock
2024-05-08	Peng Stanford L	Buy	22 593	Common Stock
2024-05-08	Peng Stanford L	Buy	161 492	Common Stock
2024-05-08	Peng Stanford L	Sell	13 377	Stock Option (Right to buy)

INSIDER POWER
-17.33
Last 100 transactions
Buy: 5 495 435 \| Sell: 7 975 820

Volume Correlation

Long: -0.29 (neutral)

Short: -1.00 (very strong negative)

Signal:(35) Neutral

Alpine Immune Sciences Correlation

10 Most Positive Correlations
NKTR	0.961
BCSA	0.956
IVCB	0.949
NSYS	0.949
BOCN	0.946
GDST	0.941
PRIM	0.939
PAYS	0.938
GALT	0.937
RZLT	0.936

10 Most Negative Correlations
ALLR	-0.966
JACK	-0.959
PERI	-0.958
AKTX	-0.954
WNEB	-0.953
SIRI	-0.952
APVO	-0.95
HAIN	-0.948
XPON	-0.948
OSUR	-0.948

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alpine Immune Sciences Correlation - Currency/Commodity

0.03
( neutral )

0.44
( neutral )

0.00
( neutral )

0.20
( neutral )

Alpine Immune Sciences Financials

Annual	2023
Revenue:	$58.88M
Gross Profit:	$58.30M (99.02 %)
EPS:	$-0.640

FY	2023
Revenue:	$58.88M
Gross Profit:	$58.30M (99.02 %)
EPS:	$-0.640

FY	2022
Revenue:	$30.06M
Gross Profit:	$29.47M (98.01 %)
EPS:	$-1.730

FY	2021
Revenue:	$23.44M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.980

Financial Reports:

No articles found.

Alpine Immune Sciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alpine Immune Sciences

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.